

Next Edge Biotech and Life Sciences Opportunities Fund  
Quarterly Summary of Investment Portfolio as at March 31, 2023



Portfolio by Asset Mix	% of Net Asset Value	
	Long	Short
United States Equity	63.3	-
Canadian Equity	15.7	-
Foreign Equity	9.2	-
Equity Options	4.7	-
Canadian Bond	2.5	-
United States Bond	1.3	-
Cash and Cash Equivalents	3.7	-
	100.4	-
Other Net Assets (Liabilities)	-	(0.04)
	100.4	(0.04)

Portfolio by Sector	% of Net Asset Value	
	Long	Short
Pharmaceuticals, Biotechnology & Life Sciences	62.2	-
Health Care Equipment & Services	24.3	-
Equity Options	4.7	-
Canadian Bond	2.6	-
Biotechnology	1.6	-
United States Bond	1.3	-
Cash and Cash Equivalents	3.7	-
	100.4	-
Other Net Assets (Liabilities)	-	(0.04)
	100.4	(0.04)

Portfolio by Geography	% of Net Asset Value	
	Long	Short
United States	64.6	-
Canada	22.9	-
International	9.2	-
Cash and Cash Equivalents	3.7	-
	100.4	-
Other Net Assets (Liabilities)	-	(0.04)
	100.4	(0.04)

# Next Edge Biotech and Life Sciences Opportunities Fund

## Quarterly Summary of Investment Portfolio as at March 31, 2023



### Top 25 Long Positions<sup>1</sup>

### % of Net Asset Value

Schrodinger Inc.	5.4
Exelixis Inc.	5.1
Cash and cash equivalent	3.7
Microbix Biosystems Inc.	3.3
NuVasive Inc.	3.3
CTI BioPharma Corp.	3.0
10X Genomics Inc.	2.9
Pacific Biosciences of California Inc.	2.9
Tandem Diabetes Care Inc.	2.8
ClearPoint Neuro Inc.	2.8
Orchard Therapeutics PLC	2.8
Bluebird Bio Inc.	2.7
Apellis Pharmaceuticals Inc.	2.6
CRISPR Therapeutics AG	2.6
Opsens Inc.	2.6
Imagin Medical Inc., Private Bond, September 03, 2023	2.5
Cognition Therapeutics Inc.	2.2
Galapagos NV	2.2
Arcutis Biotherapeutics Inc.	2.1
Alector Inc.	1.8
Acumen Pharmaceuticals Inc.	1.7
Vicarious Surgical Inc.	1.6
MeiraGTx Holdings PLC	1.6
Cognetivity Neurosciences Ltd.	1.6
Iovance Biotherapeutics Inc.	1.6

**Net Asset Value of Next Edge Biotech and Life Sciences Opportunities Fund as at Mar 31, 2023**

**\$10,261,252**

1. There are no short positions as at March 31, 2023